Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
27 6월 2024 - 1:46AM
Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq:
TVGN), a clinical-stage specialty immunotherapy biotech pioneer
developing off-the-shelf, genetically unmodified T cell
therapeutics in oncology, neurology, and virology, filed a
Registration Statement on Form S-1 on June 21, 2024, to register
the issuance of previously disclosed shares of the Company’s common
stock as well as the resale of shares of common stock and warrants
by existing securityholders. This new registration statement does
not relate to any previously undisclosed new issuances of dilutive
securities.
Tevogen’s new registration statement relates to the issuance of
shares of common stock upon the exercise of previously disclosed
warrants and upon the achievement of stock price thresholds
pursuant to previously disclosed earnout provisions contained in
the merger agreement relating to the business combination between
Semper Paratus Acquisition Corporation (n/k/a Tevogen Bio Holdings
Inc.) and Tevogen Bio Inc. The warrants, which have an exercise
price of $11.50 per share, were originally issued by Semper Paratus
Acquisition Corporation in 2021. The earnout shares, which require
Tevogen’s common stock to reach a threshold price of at least
$15.00 per share over a specified time period to trigger any
issuance, were previously registered on the Registration Statement
on Form S-4 (File No. 333-274519) originally filed with the
Securities and Exchange Commission on September 14, 2023.
In addition, the registration statement relates to the resale by
selling securityholders of warrants and shares of common stock that
were issued or are issuable in connection with previously disclosed
issuances of securities by the Company.
The new registration statement has not yet been declared
effective by the Securities and Exchange Commission.
No Offer or Solicitation
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor will there be
any sale of securities in any states or jurisdictions in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such
jurisdiction. No offer of securities shall be made except by means
of a prospectus meeting the requirements of the Securities Act of
1933, as amended.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically
unmodified precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders, aiming to
address the significant unmet needs of large patient populations.
Tevogen Leadership believes that sustainability and commercial
success in the current era of healthcare rely on ensuring patient
accessibility through advanced science and innovative business
models. Tevogen has reported positive safety data from its
proof-of-concept clinical trial, and its key intellectual property
assets are wholly owned by the company, not subject to any
third-party licensing agreements. These assets include three
granted patents, nine pending US and twelve ex-US pending patents,
two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry
leaders and distinguished scientists with drug development and
global product launch experience. Tevogen’s leadership believes
that accessible personalized therapeutics are the next frontier of
medicine, and that disruptive business models are required to
sustain medical innovation.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGNW)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Tevogen Bio (NASDAQ:TVGNW)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024